Related Experiment Video
Updated: May 29, 2026

Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin
Sarah J Petit1, Caroline Blondeau1, Greg J Towers1
1MRC Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, Cruciform Building, 90 Gower Street, London WC1E 6BT, UK.
Abstract:
Zoonosis of chimpanzee simian immunodeficiency virus cpz to humans has given rise to both pandemic (M) and non-pandemic (O, N and P) groups of human immunodeficiency virus type-1 (HIV). These lentiviruses encode accessory proteins, including Vpu, which has been shown to reduce CD4 levels on the cell surface, as well as increase virion release from the cell by antagonizing tetherin (CD317, BST2). Here, we confirm that O group Vpus (Ca9 and BCF06) are unable to counteract tetherin or downregulate the protein from the cell surface, although they are still able to reduce cell-surface CD4 levels. We hypothesize that this inability to antagonize tetherin may have contributed to O group viruses failing to achieve pandemic levels of human-to-human transmission. Characterization of chimeric O/M group Vpus and Vpu mutants demonstrate that the Vpu-tetherin interaction is complex, involving several domains. We identify specific residues within the transmembrane proximal region that, along with the transmembrane domain, are crucial for tetherin counteraction and enhanced virion release. We have also shown that the critical domains are responsible for the localization of M group Vpu to the trans-Golgi network, where it relocalizes tetherin to counteract its function. This work sheds light on the acquisition of anti-tetherin activity and the molecular details of pandemic HIV infection in humans.
Insights
Human immunodeficiency virus type-1 (HIV) O group Vpu proteins cannot antagonize tetherin, potentially explaining their limited human-to-human transmission. This study reveals key Vpu domains for tetherin interaction and HIV pandemic spread.
Area of Science:
- Virology
- Molecular Biology
- Immunology
Background:
- Human immunodeficiency virus type-1 (HIV) originated from simian immunodeficiency virus (SIVcpz) in chimpanzees, leading to pandemic (HIV-1 group M) and non-pandemic (groups O, N, P) strains.
- The accessory protein Vpu is crucial for HIV replication, mediating CD4 downregulation and virion release by antagonizing tetherin (BST2).
Purpose of the Study:
- To investigate why HIV-1 group O Vpu proteins are less effective at antagonizing tetherin compared to group M.
- To identify the molecular mechanisms underlying Vpu's interaction with tetherin and its role in HIV pandemic potential.
Main Methods:
- Comparative analysis of Vpu proteins from HIV-1 group O and group M viruses.
- Construction and characterization of chimeric Vpu proteins and Vpu mutants.
- Assessment of Vpu's ability to counteract tetherin, downregulate cell-surface CD4, and promote virion release.
- Investigation of Vpu's cellular localization, particularly its interaction with the trans-Golgi network.
Main Results:
- HIV-1 group O Vpu proteins (Ca9, BCF06) failed to antagonize tetherin or downregulate it from the cell surface, despite reducing cell-surface CD4 levels.
- Chimeric Vpu proteins and mutants revealed that specific residues in the transmembrane proximal region and the transmembrane domain are critical for tetherin antagonism and enhanced virion release.
- Group M Vpu localization to the trans-Golgi network is essential for tetherin relocalization and antagonism.
Conclusions:
- The inability of group O Vpu to antagonize tetherin is a significant factor limiting the pandemic potential of these viruses.
- The Vpu-tetherin interaction is complex, involving specific molecular domains and cellular localization, which are key determinants of HIV pandemic spread.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Inhibitors Of Virion Release
Intralumenal Vesicles and Multivesicular Bodies

